PATRYS LIMITED (PAB)

---

AI Coverage Rating: Moderate

ASX AI Signals has generated 1 signal(s) for PAB during the last 90 days, indicating Moderate trading activity

Latest PAB Signals
16/06/2026	BUY
PAB Share Price
Current Price	$0.039
52 Week High	$0.049
52 Week Low:	$0.012
Trading at (% of 52 Week High)	79.59%

Business Overview

Patrys Limited (ASX: PAB) is a biotechnology company focused on developing novel antibody-based therapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary antibody platform to create treatments aimed at improving patient outcomes. Patrys is headquartered in Australia and operates with a focus on advancing its pipeline through research and development.

ASX Sector Overview

Sector:   Pharmaceuticals, Biotechnology & Life Sciences

The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.

Latest AI Recommendation

The BUY signal for PAB at the current price of 0.0490 reflects potential upside, but the low price and limited available data suggest higher volatility and uncertainty. Caution is advised due to liquidity and market depth concerns.

Latest  PATRYS LIMITED(PAB)   News